Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer.

CONTEXT Interstitial radiation (implant) therapy is used to treat clinically localized adenocarcinoma of the prostate, but how it compares with other treatments is not known. OBJECTIVE To estimate control of prostate-specific antigen (PSA) after radical prostatectomy (RP), external beam radiation (RT), or implant with or without neoadjuvant androgen deprivation therapy in patients with clinically localized prostate cancer. DESIGN Retrospective cohort study of outcome data compared using Cox regression multivariable analyses. SETTING AND PATIENTS A total of 1872 men treated between January 1989 and October 1997 with an RP (n = 888) or implant with or without neoadjuvant androgen deprivation therapy (n = 218) at the Hospital of the University of Pennsylvania, Philadelphia, or RT (n = 766) at the Joint Center for Radiation Therapy, Boston, Mass, were enrolled. MAIN OUTCOME MEASURE Actuarial freedom from PSA failure (defined as PSA outcome). RESULTS The relative risk (RR) of PSA failure in low-risk patients (stage T1c, T2a and PSA level < or =10 ng/mL and Gleason score < or =6) treated using RT, implant plus androgen deprivation therapy, or implant therapy was 1.1 (95% confidence interval [CI], 0.5-2.7), 0.5 (95% CI, 0.1-1.9), and 1.1 (95% CI, 0.3-3.6), respectively, compared with those patients treated with RP. The RRs of PSA failure in the intermediate-risk patients (stage T2b or Gleason score of 7 or PSA level >10 and < or =20 ng/mL) and high-risk patients (stage T2c or PSA level >20 ng/mL or Gleason score > or =8) treated with implant compared with RP were 3.1 (95% CI, 1.5-6.1) and 3.0 (95% CI, 1.8-5.0), respectively. The addition of androgen deprivation to implant therapy did not improve PSA outcome in high-risk patients but resulted in a PSA outcome that was not statistically different compared with the results obtained using RP or RT in intermediate-risk patients. These results were unchanged when patients were stratified using the traditional rankings of biopsy Gleason scores of 2 through 4 vs 5 through 6 vs 7 vs 8 through 10. CONCLUSIONS Low-risk patients had estimates of 5-year PSA outcome after treatment with RP, RT, or implant with or without neoadjuvant androgen deprivation that were not statistically different, whereas intermediate- and high-risk patients treated with RP or RT did better then those treated by implant. Prospective randomized trials are needed to verify these findings.

[1]  A. D'Amico,et al.  Outcome based staging for clinically localized adenocarcinoma of the prostate. , 1997, The Journal of urology.

[2]  J. Blasko,et al.  Interstitial iodine‐125 radiation without adjuvant therapy in the treatment of clinically localized prostate carcinoma , 1997, Cancer.

[3]  A. D'Amico,et al.  Prostate-specific antigen failure despite pathologically organ-confined and margin-negative prostate cancer: the basis for an adjuvant therapy trial. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  A. D'Amico,et al.  Equivalent biochemical failure-free survival after external beam radiation therapy or radical prostatectomy in patients with a pretreatment prostate specific antigen of > 4-20 ng/ml. , 1997, International journal of radiation oncology, biology, physics.

[5]  James D. Cox,et al.  Consensus statement: Guidelines for PSA following radiation therapy , 1997 .

[6]  H. Levin,et al.  Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy. , 1997, International journal of radiation oncology, biology, physics.

[7]  M. Kahn,et al.  A multiple prognostic index predictive of disease outcome after irradiation for clinically localized prostate carcinoma , 1997, Cancer.

[8]  D. Bostwick,et al.  Analysis of risk factors for progression in patients with pathologically confined prostate cancers after radical retropubic prostatectomy. , 1996, The Journal of urology.

[9]  J Roy,et al.  Tumor control and morbidity following transperineal iodine 125 implantation for stage T1/T2 prostatic carcinoma. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  J. Blasko,et al.  Prostate specific antigen based disease control following ultrasound guided 125iodine implantation for stage T1/T2 prostatic carcinoma. , 1995, The Journal of urology.

[11]  J. Oesterling,et al.  Free, complexed and total serum prostate specific antigen: the establishment of appropriate reference ranges for their concentrations and ratios. , 1995, The Journal of urology.

[12]  T. Schultheiss,et al.  Clinical and biochemical evidence of control of prostate cancer at 5 years after external beam radiation. , 1995, The Journal of urology.

[13]  J. Adolfsson Deferred treatment for clinically localized prostate cancer. , 1995, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[14]  A Pollack,et al.  Prostate-specific antigen and radiation therapy for clinically localized prostate cancer. , 1995, International journal of radiation oncology, biology, physics.

[15]  F. Marshall,et al.  Selection of men at high risk for disease recurrence for experimental adjuvant therapy following radical prostatectomy. , 1995, Urology.

[16]  M. Hunt,et al.  Localized prostate cancer treated by external-beam radiotherapy alone: serum prostate-specific antigen--driven outcome analysis. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  P. Walsh Results of conservative management of clinically localized prostate cancer. , 1994, The Journal of urology.

[18]  A. Zietman,et al.  Radical prostatectomy for adenocarcinoma of the prostate: the influence of preoperative and pathologic findings on biochemical disease-free outcome. , 1994, Urology.

[19]  A. Zietman,et al.  Radical radiation therapy in the management of prostatic adenocarcinoma: the initial prostate specific antigen value as a predictor of treatment outcome. , 1994, The Journal of urology.

[20]  S. Cha,et al.  Prostate-specific antigen as a pretherapy prognostic factor in patients treated with radiation therapy for clinically localized prostate cancer. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  I. Thompson,et al.  Salvage radical prostatectomy for adenocarcinoma of the prostate , 1988, Cancer.

[22]  D. Gleason,et al.  Histologic Grading and Staging of Prostatic Carcinoma , 1981 .

[23]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[24]  D.,et al.  Regression Models and Life-Tables , 2022 .